Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Liabilities and Shareholders Equity (2016 - 2026)

Champions Oncology has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $28.4 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $28.4 million for Q1 2026, down 7.12% from a year ago — trailing twelve months through Jan 2026 was $121.5 million (up 13.62% YoY), and the annual figure for FY2025 was $32.3 million, up 23.77%.
  • Liabilities and Shareholders Equity for Q1 2026 was $28.4 million at Champions Oncology, down from $30.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CSBR hit a ceiling of $36.4 million in Q4 2022 and a floor of $24.9 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $30.5 million (2025), compared with a mean of $30.8 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 32.95% in 2022 and later decreased 25.9% in 2024.
  • Champions Oncology's Liabilities and Shareholders Equity stood at $36.4 million in 2022, then decreased by 22.19% to $28.3 million in 2023, then fell by 10.79% to $25.2 million in 2024, then rose by 19.5% to $30.2 million in 2025, then dropped by 5.69% to $28.4 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $28.4 million (Q1 2026), $30.2 million (Q4 2025), and $30.5 million (Q3 2025) per Business Quant data.